Importantly, TGF-β promotes PD-1 expression in antigen-specific T cells via SMAD3 activation, suggesting that increased levels of TGF-β in obesity could be a potential biomarker for anti-PD-1 therapy (158). This evidence concerns the gene TGFB1 and obesity due to melanocortin 4 receptor deficiency.